Immunovant, Inc. Files 8-K
Ticker: IMVT · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1764013
Sentiment: neutral
Topics: sec-filing, corporate-update
Related Tickers: IMVT
TL;DR
IMVT filed an 8-K on 1/24/25 - routine update.
AI Summary
Immunovant, Inc. filed an 8-K on January 24, 2025, reporting other events and financial statements. The company, formerly known as Health Sciences Acquisitions Corp. until January 8, 2019, is incorporated in Delaware and headquartered in New York, NY.
Why It Matters
This filing indicates a routine update or disclosure from Immunovant, Inc. to the SEC, which may contain important information for investors regarding company events or financial status.
Risk Assessment
Risk Level: low — This 8-K filing appears to be a standard disclosure and does not immediately indicate any significant negative events or risks.
Key Numbers
- 001-38906 — SEC File Number (Identifies the company's filing with the SEC)
- 83-2771572 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Immunovant, Inc. (company) — Registrant
- Health Sciences Acquisitions Corp. (company) — Former company name
- January 24, 2025 (date) — Date of report
- January 8, 2019 (date) — Date of name change
- Delaware (jurisdiction) — State of incorporation
- New York, NY (location) — Principal executive offices
FAQ
What specific events are detailed in the 'Other Events' section of this 8-K filing?
The provided text does not specify the 'Other Events'; it only indicates that this item is included in the filing.
What is the purpose of filing an 8-K form?
An 8-K form is used to announce major corporate events that shareholders should know about in a timely manner.
When did Immunovant, Inc. change its name from Health Sciences Acquisitions Corp.?
The company changed its name on January 8, 2019.
Where are Immunovant, Inc.'s principal executive offices located?
The principal executive offices are located at 320 West 37th Street, New York, NY 10018.
What is Immunovant, Inc.'s fiscal year end?
Immunovant, Inc.'s fiscal year ends on March 31.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-01-24 17:24:41
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMVT The Nasdaq
Filing Documents
- d920756d8k.htm (8-K) — 25KB
- d920756dex51.htm (EX-5.1) — 9KB
- g920756g0124042029209.jpg (GRAPHIC) — 2KB
- 0001193125-25-012329.txt ( ) — 157KB
- imvt-20250124.xsd (EX-101.SCH) — 3KB
- imvt-20250124_lab.xml (EX-101.LAB) — 17KB
- imvt-20250124_pre.xml (EX-101.PRE) — 11KB
- d920756d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (contained in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOVANT, INC. By: /s/ Eva Renee Barnett Eva Renee Barnett Chief Financial Officer Date: January 24, 2025